XNASFEMY
Market cap25mUSD
Dec 24, Last price
1.11USD
1D
3.74%
1Q
-1.77%
IPO
-89.77%
Name
Femasys Inc
Chart & Performance
P/E
—
P/S
23.71
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
1m
-11.13%
Net income
-14m
L+25.04%
CFO
-11m
L+5.11%
Profile
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 1,072 -11.13% | 1,206 2.25% | 1,180 13.66% | ||
Cost of revenue | 15,097 | 12,245 | 8,925 | ||
Unusual Expense (Income) | |||||
NOPBT | (14,025) | (11,039) | (7,746) | ||
NOPBT Margin | |||||
Operating Taxes | 4 | 6 | 4 | ||
Tax Rate | |||||
NOPAT | (14,029) | (11,045) | (7,750) | ||
Net income | (14,247) 25.04% | (11,394) 51.16% | (7,538) 9.01% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 11,565 | (153) | 31,740 | ||
BB yield | -77.10% | 1.44% | -68.95% | ||
| Debt | |||||
Debt current | 813 | 515 | 588 | ||
Long-term debt | 8,737 | 431 | 1,212 | ||
Deferred revenue | (20,378) | ||||
Other long-term liabilities | 55 | 97 | 150 | ||
Net debt | (12,166) | (12,016) | (2,605) | ||
| Cash flow | |||||
Cash from operating activities | (11,281) | (10,732) | (7,931) | ||
CAPEX | (144) | (407) | (307) | ||
Cash from investing activities | (144) | (407) | (307) | ||
Cash from financing activities | 20,179 | (682) | 29,698 | ||
FCF | (15,561) | (10,740) | (7,129) | ||
| Balance | |||||
Cash | 21,716 | 12,962 | 24,783 | ||
Long term investments | (20,378) | ||||
Excess cash | 21,662 | 12,902 | 4,346 | ||
Stockholders' equity | (108,360) | (93,555) | (82,728) | ||
Invested Capital | 133,875 | 109,411 | 89,719 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 15,384 | 11,804 | 11,804 | ||
Price | 0.98 8.33% | 0.90 -76.92% | 3.90 | ||
Market cap | 15,000 41.19% | 10,624 -76.92% | 46,036 | ||
EV | 2,834 | (1,392) | 72,008 | ||
EBITDA | (13,117) | (10,150) | (6,781) | ||
EV/EBITDA | 0.14 | ||||
Interest | 165 | 13 | 19 | ||
Interest/NOPBT | |||||